RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Repligen Corporation

Criteria

Mitochondrial Disease